Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Medronic Acid→

Medronic Acid PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1984-15-2
Molecular formula
CH6O6P2
Molecular weight
176 g/mol
Drug class
Bisphosphonate liganddiagnostic radiopharmaceutical precursor for technetium-99m skeletal imaging
Mechanism of action
Medronic acid (methylene diphosphonate, MDP) chelates technetium-99m after reconstitution of a radiopharmaceutical kit. The labelled complex has affinity for hydroxyapatite in bone and accumulates in proportion to regional blood flow and osteoblastic activity, allowing skeletal scintigraphy.
Indications / reported uses
  • Used as the active ligand in technetium Tc-99m medronate (Tc-99m MDP) kits for skeletal scintigraphy and imaging of areas of increased osteogenic activity. The diagnostic imaging agent is the technetium-labelled product, not unlabelled medronic acid alone.

Sources: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/technetium-tc-99m-medronate · https://www.safetyandquality.gov.au/medicine-finder/radpharm-mdp · https://www.ncbi.nlm.nih.gov/mesh/68013669

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Bisphosphonate ligand; diagnostic radiopharmaceutical precursor for technetium-99m skeletal imaging

Mechanism of action

Medronic acid (methylene diphosphonate, MDP) chelates technetium-99m after reconstitution of a radiopharmaceutical kit. The labelled complex has affinity for hydroxyapatite in bone and accumulates in proportion to regional blood flow and osteoblastic activity, allowing skeletal scintigraphy.

General use cases

  • Used as the active ligand in technetium Tc-99m medronate (Tc-99m MDP) kits for skeletal scintigraphy and imaging of areas of increased osteogenic activity. The diagnostic imaging agent is the technetium-labelled product, not unlabelled medronic acid alone.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Medronic Acid PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Medronic Acid Permitted Daily Exposure (PDE) report (the Medronic Acid PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Medronic Acid Occupational Exposure Limit (OEL) report (the Medronic Acid OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.